Leisti S, Koskimies O
J Pediatr. 1983 Oct;103(4):553-7. doi: 10.1016/s0022-3476(83)80582-4.
Glucocorticoid therapy has been effective in inducing remission in the majority of children with primary nephrotic syndrome. However, glucocorticoid-induced adrenocortical suppression is associated with early relapse, whereas normal adrenocortical function seems to delay the subsequent relapse. We analyzed 201 episodes of prednisone treatment in 47 children with steroid-sensitive nephrotic syndrome by the life-table method. The effect of partial cortisol substitution was studied as well. Adrenocortical function was determined by a two-hour ACTH test. A response of 50% to 100% of the minimum normal response was diagnosed as "moderate" suppression, and a response of less than 50% as "severe." Post-prednisone adrenocortical function was normal in 99 episodes (49%). Adrenocortical suppression occurred in 102 episodes; of these, 68 were considered moderate and 34 severe. Adrenocortical suppression increased both the initial relapse rate and the final risk of a relapse. Severe suppression was always associated with a relapse, the longest remission time being 0.5 year. In moderate suppression, several long, relapse-free intervals were observed, but the risk of relapse was still higher than in episodes with normal adrenocortical function. Cortisol substitution possibly decreased the risk of a relapse after severe adrenocortical suppression, but not after moderate suppression.
糖皮质激素疗法对大多数原发性肾病综合征患儿诱导缓解有效。然而,糖皮质激素诱导的肾上腺皮质抑制与早期复发相关,而正常肾上腺皮质功能似乎可延迟随后的复发。我们采用寿命表法分析了47例激素敏感型肾病综合征患儿的201次泼尼松治疗情况。同时研究了部分皮质醇替代的效果。通过两小时促肾上腺皮质激素(ACTH)试验测定肾上腺皮质功能。将最小正常反应的50%至100%的反应诊断为“中度”抑制,小于50%的反应诊断为“重度”。99次(49%)泼尼松治疗后肾上腺皮质功能正常。102次出现肾上腺皮质抑制;其中68次为中度,34次为重度。肾上腺皮质抑制增加了初始复发率和最终复发风险。重度抑制总是与复发相关,最长缓解时间为0.5年。在中度抑制中,观察到几个较长的无复发间期,但复发风险仍高于肾上腺皮质功能正常的治疗期。皮质醇替代可能降低重度肾上腺皮质抑制后的复发风险,但对中度抑制无效。